Drugs / Survivin peptide
last change Sep 2016 re-read 2 minutes ago

Survivin peptide

Peptide

Developed for
melanoma
Investigated by
Copenhagen University Hospital at Herlev · Inge Marie Svane

Trials 1 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01543464 May 2012 → Sep 2016 melanoma Inge Marie Svane Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Survivin peptide “Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week” NCT01543464
Modality Peptide “Survivin peptideNCT01543464